Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher and former head of GlaxoSmithKline’s vaccines department. On May 15, 2020, President Donald Trump announced that Sl aoui would manage the U.S. government’s development of a vaccine used to treat coronavirus disease in Operation Warp Speed.
About Moncef Slaoui in brief
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher and former head of GlaxoSmithKline’s vaccines department. He worked at the company for thirty years, retiring in 2017. On May 15, 2020, President Donald Trump announced that Sl aoui would manage the U.S. government’s development of a vaccine used to treat coronavirus disease in Operation Warp Speed. Other candidates for the position reportedly included Elias Zerhouni and Arthur Levinson. SlaOUi was born on July 22, 1959, in Agadir, Morocco. He left Morocco at age 17 to study medicine in France but missed the registration deadline due to new registration procedures and his mother being ill. In 1983, he earned a PhD in molecular biology and immunology from the Free University of Brussels.
In 1998, he received an accelerated MBA from the International Institute for Management Development in Lausanne, Switzerland. In April 2013, he co-wrote a paper with several other GSK heads that introduced the term ‘electroceutical’ to broadly encompass medical devices that use electrical, mechanical, or light stimulation to affect electrical signaling in relevant tissue types. In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost USD 100 million; it ceased operations in August 2017.
You want to know more about Moncef Slaoui?
This page is based on the article Moncef Slaoui published in Wikipedia (as of Dec. 08, 2020) and was automatically summarized using artificial intelligence.
